A pragmatic trial to evaluate the intermediate-term effects of early aggressive versus escalation therapy in people with multiple sclerosis

Go Back to All Clinical Trials

A pragmatic trial to evaluate the intermediate-term effects of early aggressive versus escalation therapy in people with multiple sclerosis

Brief description of study

The TREAT-MS trial (TRaditional versus Early Aggressive Therapy for MS) is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an “early aggressive” therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

Clinical Study Identifier: s17-01576

ClinicalTrials.gov Identifier: NCT03500328

Principal Investigator: Tyler Ellis Smith.

Other Investigators: Carrie Lyn Sammarco, Gabriella Frances Brogna, Vito Pasquale Arena, Ilya Kister, Jonathan E Howard, Jennifer K Abate, Robert W Charlson.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies